Resonance Health Hisse

Resonance Health EBITDA

Resonance Health (RHT.AX) öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 8 Ağu 2026 itibarıyla -875.300,00 AUD dir. Önceki yılda, EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) -167.300,00 AUD idi — 423,19% (daha düşük) bir değişiklik.

EBITDA

-875.300,00AUD

YoY

423,19%

Son güncelleme:

Resonance Health öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 -875.300,00 AUD dir. Resonance Health öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2025 -167.300,00 AUD idi. %423,19 daha düşük önceki yıla kıyasla azalmaktadır.
Access this data via the Eulerpool API

Resonance Health Hisse senedi analizi

Resonance Health ne yapar? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health, Eulerpool'daki en popüler şirketlerden biridir.

Resonance Health hisse senedi hakkında sık sorulan sorular

Resonance Health şirketinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 yılında -875.300,00 AUD.

Resonance Health öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri -167.300,00 AUD değerinden -875.300,00 AUD değerine değişmiş ve bu %423,19 değişimi temsil etmektedir. Değer önceki yıldan daha düşük dir.

Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) öğesinin Resonance Health değerinin 2006'dan itibaren tam tarihsel gelişimini bulabilirsiniz — yıllık değerler, grafikler ve ayrıntılı analiz ile.

EBITDA, finansal yapı, vergi ortamı ve nakit olmayan amortisman giderleri etkisinden önceki işletme performansını ölçer.

EBITDA = EBIT + Amortisman

EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin AUD, yatırımcılar için kilit bir faktördür. Bu metrikte yapılan değişiklikler temel faktörlerin iyileşmesini veya kötüleşmesini gösterebilir ve hisse senedi fiyatını doğrudan etkiler. Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin Resonance Health değerini tarihsel olarak ve gerçek zamanlı olarak takip edebilirsiniz.

Access this data via the Eulerpool API

Gelir Tablosu — Resonance Health

Tüm Kilit Metrikler — Resonance Health